Results 221 to 230 of about 67,820 (304)

Disarming the Hsp70–Bim Alliance: Small‐Molecule and Peptidic Disruptors of a Chaperone‐Apoptotic Switch in Cancer

open access: yesChemistryOpen, EarlyView.
Targeting a nucleotide‐sensitive groove on Hsp70 that binds the Bim BH3 helix, we integrate structures, biophysics, and SAR from peptides, fragments, and phenalene‐dicarbonitrile “wedges.” These disrupt the Hsp70–Bim complex with sub‐µM cellular engagement and in vivo activity while sparing Hsp90/mortalin.
Emadeldin M. Kamel   +5 more
wiley   +1 more source

Clinicopathological characteristics of patients with inoperable non‐small cell lung cancer harboring circulating NRF2 pathway mutations

open access: yesThe Journal of Pathology, EarlyView.
Abstract Lung cancer is the leading cause of global cancer‐related morbidity and mortality, with tobacco smoking as its strongest risk factor. Nuclear factor erythroid 2‐related factor 2 (NRF2) is a redox‐regulated transcription factor frequently dysregulated in non‐small cell lung cancer (NSCLC), leading to aggressive disease and resistance to therapy.
Jouni Härkönen   +14 more
wiley   +1 more source

<i>De Novo</i>-Designed APC/C Inhibitors Provide a Rationale for Targeting RING-Type E3 Ubiquitin Ligases. [PDF]

open access: yesJ Med Chem
Ruiz-Gómez G   +5 more
europepmc   +1 more source

Proteome Analysis of Corynebacterium diphtheriae–Macrophage Interaction

open access: yesPROTEOMICS, EarlyView.
ABSTRACT Contact of Corynebacterium diphtheriae with macrophages induces adaptations on both bacterial and cellular sides. The study presented here was aiming to shed light on the simultaneous intracellular adaptation of the bacteria and changes in the proteome of the phagocytes in response to the internalization of C. diphtheriae.
Luca Musella   +6 more
wiley   +1 more source

The tumor necrosis factor receptor superfamily in lung cancer immunotherapy: Therapeutic opportunities and challenges

open access: yesPrecision Medical Sciences, EarlyView.
TNFRSF members orchestrate a dynamic immunoregulatory network in lung cancer by coordinating co‐stimulatory and inhibitory signaling across immune cell populations, highlighting their potential as targets for precision immunotherapy. Abstract Immune checkpoint blockade has fundamentally reshaped the therapeutic landscape of lung cancer.
Bingjie Xue   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy